Login to Your Account



Interim Data Presented at AACR

Activartis in Partnering Talks Armed with Phase II Survival

By Nuala Moran
Staff Writer

Wednesday, April 10, 2013
Cancer specialist Activartis Biotech GmbH will present positive survival data from the Phase II trial of its dendritic cell therapy in treating glioblastoma at the American Association of Cancer Research (AACR) Wednesday, as it steps up efforts to find a partner to back a Phase III study.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription